New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 1, 2013
13:25 EDTBMRN, BMRN, BMRN, CLVS, CLVS, CLVS, TSRO, TSRO, TSROLeerink's biotech analysts hold an analyst/industry conference call
Biotech Analysts Kozul, Liang and Schwartz provide a review of development programs for novel oral PARPs (Poly(ADP-ribose) polymerase); Biomarin's BMN-673, Clovis Oncology's Rucaparin and Tesaro's Niraparib on an Analyst/Industry conference call to be held on February 4 at 2 pm.
News For BMRN;CLVS;TSRO From The Last 14 Days
Check below for free stories on BMRN;CLVS;TSRO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 23, 2014
08:10 EDTBMRNBioMarin, Sarah Cannon Research UK collaborate on EMBRACA clinical study
BioMarin Pharmaceutical and Sarah Cannon Research UK announced a collaboration to enroll patients in an ongoing Phase 3 clinical trial of its PARP inhibitor, BMN 673, for the treatment of hereditary breast cancer with a BRCA mutation. This ongoing Phase 3 trial has recently been named EMBRACA. Sarah Cannon Research UK enrolled the first patient outside of the United States, expanding the trial internationally.
07:44 EDTBMRNBioMarin survey shows strong Vimizim demand, says Leerink
Subscribe for More Information
July 15, 2014
10:56 EDTBMRNFed calls small cap social media, biotech valuations 'stretched'
The Board of Governors of the Federal Reserve in its Monetary Policy Report dated today said valuation metrics in "some sectors" appear substantially stretched, "particularly those for smaller firms in the social media and biotechnology industries, despite a notable downturn in equity prices for such firms early in the year." A later part in the document reads, "Equity valuations of smaller firms as well as social media and biotechnology firms appear to be stretched, with ratios of prices to forward earnings remaining high relative to historical norms." The specific targeting of sectors by the Fed seems to be having an impact on stocks in the social media and biotech spaces. Shares of Yelp (YELP) are down over 5% to $67.51, while Twitter (TWTR) and Facebook (FB) are each down 2%. Celgene (CELG) and Amgen (AMGN) are leading the biotech space lower with pullbacks of greater than 1%.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use